MX2020012700A - Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida. - Google Patents

Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida.

Info

Publication number
MX2020012700A
MX2020012700A MX2020012700A MX2020012700A MX2020012700A MX 2020012700 A MX2020012700 A MX 2020012700A MX 2020012700 A MX2020012700 A MX 2020012700A MX 2020012700 A MX2020012700 A MX 2020012700A MX 2020012700 A MX2020012700 A MX 2020012700A
Authority
MX
Mexico
Prior art keywords
acid sphingomyelinase
pharmaceutical compositions
treating acid
sphingomyelinase deficiency
compositions
Prior art date
Application number
MX2020012700A
Other languages
English (en)
Inventor
Claudia Buser
Mark Yang
Ramirez Bernardo Perez-
Grant Trierweiler
Sangeeta Benjwal
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2020012700A publication Critical patent/MX2020012700A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona composiciones, tales como composiciones líquidas acuosas y composiciones liofilizadas, que comprenden una esfingomielinasa ácida humana recombinante. También se proporcionan métodos para usar las composiciones para el tratamiento de pacientes que tienen una deficiencia de esfingomielinasa ácida.
MX2020012700A 2018-05-25 2019-05-24 Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida. MX2020012700A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676525P 2018-05-25 2018-05-25
PCT/US2019/033983 WO2019227029A1 (en) 2018-05-25 2019-05-24 Pharmaceutical compositions for treating acid sphingomyelinase deficiency

Publications (1)

Publication Number Publication Date
MX2020012700A true MX2020012700A (es) 2021-04-28

Family

ID=66912954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012700A MX2020012700A (es) 2018-05-25 2019-05-24 Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida.

Country Status (14)

Country Link
US (1) US20210145941A1 (es)
EP (1) EP3802805A1 (es)
JP (1) JP2024069459A (es)
KR (1) KR20210015903A (es)
CN (1) CN112424347A (es)
AU (1) AU2019275109A1 (es)
BR (1) BR112020023829A2 (es)
CA (1) CA3101688A1 (es)
CO (1) CO2020014399A2 (es)
IL (1) IL278964A (es)
MX (1) MX2020012700A (es)
SG (1) SG11202011488WA (es)
UY (1) UY38238A (es)
WO (1) WO2019227029A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202403043A (zh) 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
EP1999270A4 (en) * 2006-03-13 2010-04-28 Perkinelmer Las Inc SUBSTRATES AND INTERNAL STANDARDS FOR MASS SPECTROSCOPY DETECTION
JP2012530721A (ja) * 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
RU2569744C2 (ru) 2009-08-28 2015-11-27 Маунт Синай Скул Оф Медсин Ферментная заместительная терапия с увеличением дозы для лечения недостаточности кислой сфингомиелиназы
RU2012154576A (ru) * 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
FI126979B (en) * 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof
KR20200044064A (ko) * 2017-08-24 2020-04-28 사노피 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료

Also Published As

Publication number Publication date
CA3101688A1 (en) 2019-11-28
AU2019275109A1 (en) 2021-01-21
BR112020023829A2 (pt) 2021-05-11
WO2019227029A1 (en) 2019-11-28
KR20210015903A (ko) 2021-02-10
JP2024069459A (ja) 2024-05-21
SG11202011488WA (en) 2020-12-30
CN112424347A (zh) 2021-02-26
JP2021525083A (ja) 2021-09-24
CO2020014399A2 (es) 2020-12-10
UY38238A (es) 2019-12-31
IL278964A (en) 2021-01-31
EP3802805A1 (en) 2021-04-14
US20210145941A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
PH12018502634A1 (en) Topical compositions of apremilast
ZA202002094B (en) Trispecific proteins and methods of use
MX2020001513A (es) Agentes de union a clec9a y su uso.
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
IN2015DN00376A (es)
MY167804A (en) Treatment of degenerative joint disease
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
MX2019011196A (es) Neurotoxinas botulinas para uso en terapia.
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2019009952A (es) Formulaciones de evolocumab de baja viscosidad y alta concentracion y metodos de elaboracion de las mismas.
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
PH12021550122A1 (en) Solubilized apyrases, methods and use
MY173174A (en) Short bio-active peptides for promoting wound healing
PL3672622T3 (pl) Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy
MX2020012700A (es) Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2016005976A (es) Formulaciones de tripeptido liofilizado estables en almacenamiento.
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy